Human Anti-CCL5 Recombinant Antibody (clone 1D9) (CAT#: HPAB-0380LY)

Figure 1 The antibody 1D9 is specific for CCR2.

L1.2 stable transfectants bearing either CCR2b, CCR5, or CCR1 on their cell surface were analyzed by flow cytometry following incubation of the cells with the specific primary antibodies 1D9 (anti-CCR2), 2D7 (anti-CCR5), or 2D4 (anti-CCR1) all at 10 g/ml and subsequent detection with a goat anti-mouse fluorescein isothiocyanate-conjugated secondary mAb.

Martinelli, R., Sabroe, I., LaRosa, G., Williams, T. J., & Pease, J. E. (2001). The CC chemokine eotaxin (CCL11) is a partial agonist of CC chemokine receptor 2b. Journal of Biological Chemistry, 276(46), 42957-42964.

Figure 2 Effects of irradiations on melanoma blood vessels.

Illustration of the methodology. White contours: CD31+. Green staining: FITC-albumin+. Arrows: nonperfused vessels (CD31+ and FITC-albumin–).

Potez, M., Fernandez-Palomo, C., Bouchet, A., Trappetti, V., Donzelli, M., Krisch, M., ... & Djonov, V. (2019). Synchrotron Microbeam Radiation Therapy as a New Approach for the Treatment of Radioresistant Melanoma: Potential Underlying Mechanisms. International Journal of Radiation Oncology* Biology* Physics, 105(5), 1126-1136.

Figure 3 Effects of irradiations on melanoma tumor cells turnover.

Representative images of microbeam radiation therapy (MRT) (left column) and broad beam (BB) (right column) irradiated tumors immunostained by KI67 (red) and DAPI (blue) at D5 and D9.